Browse By: Country ι Category ι Latest Reports ι Tag
Home  »  Global Markets Direct

Global Markets Direct Market Research Reports

Global Markets Direct is a leading provider of global business intelligence and market analysis. The company publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials.

At the heart of Global Markets Direct are unique databases, updated live, covering millions of rows of key information for the studied industry at a global level.

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016’, provides in depth analysis on Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted pipeline therapeutics. The report provides comprehensive information on the Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30), targeted therapeutics, complete with analysis by indications, stage of development, mech
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016’, provides in depth analysis on Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted pipeline therapeutics. The report provides comprehensive information on the Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers t
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3
Summary Global Markets Direct’s, ‘Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Pipeline Review, H2 2016’, provides in depth analysis on Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted pipeline therapeutics. The report provides comprehensive info
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Pipel
Summary Global Markets Direct’s, ‘TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Pipeline Review, H2 2016’, provides in depth analysis on TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted pipeline therapeutics. The report provides comprehensive information on the TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016’, provides in depth analysis on GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted pipeline therapeutics. The report provides comprehensive information on the GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in GTPase KRas (KRas 2
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Pipeline Review, H2
Summary Global Markets Direct’s, ‘Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Pipeline Review, H2 2016’, provides in depth analysis on Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted pipeline therapeutics. The report provides comprehensive information on the Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Me
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016’, provides in depth analysis on Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted pipeline therapeutics. The report provides comprehensive information on the Alpha L-Iduronidase (IDUA or EC 3.2.1.76), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics development and featur
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H2 2016’, provides in depth analysis on Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted pipeline therapeutics. The report provides comprehensive information on the Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) , targeted therapeut
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016’, provides in depth analysis on Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted pipeline therapeutics. The report provides comprehensive information on the Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Caspase 6 (Apoptotic Prote
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Pipeline Review, H2 2016’, provides in depth analysis on Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted pipeline therapeutics. The report provides comprehensive information on the Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and late
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016’, provides in depth analysis on Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted pipeline therapeutics. The report provides comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Pipeline Review, H2 2016’, provides in depth analysis on DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the rep
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
BCWorld Pharm Co. Ltd. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘BCWorld Pharm Co. Ltd. - Product Pipeline Review, 2016’, provides an overview of the BCWorld Pharm Co. Ltd.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by BCWorld Pharm Co. Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data a
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
CrystalGenomics, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘CrystalGenomics, Inc. - Product Pipeline Review, 2016’, provides an overview of the CrystalGenomics, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by CrystalGenomics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016’, provides an overview of the Primary Progressive Multiple Sclerosis (PPMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) an
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Burns - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Burns - Pipeline Review, H2 2016’, provides an overview of the Burns pipeline landscape. The report provides comprehensive information on the therapeutics under development for Burns, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burns and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Pruritus - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Pruritus - Pipeline Review, H2 2016’, provides an overview of the Pruritus pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 t
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Scar - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Scar - Pipeline Review, H2 2016’, provides an overview of the Scar pipeline landscape. The report provides comprehensive information on the therapeutics under development for Scar, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Scar and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Diabetic Gastroparesis - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Diabetic Gastroparesis - Pipeline Review, H2 2016’, provides an overview of the Diabetic Gastroparesis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. Global Markets Direct’s report features in
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Grass Pollen Allergy - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Grass Pollen Allergy - Pipeline Review, H2 2016’, provides an overview of the Grass Pollen Allergy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Grass Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. Global Markets Direct’s report features investigat
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Open-Angle Glaucoma - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Open-Angle Glaucoma - Pipeline Review, H2 2016’, provides an overview of the Open-Angle Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects. Global Markets Direct’s report features investigationa
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Ocular Hypertension - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Ocular Hypertension - Pipeline Review, H2 2016’, provides an overview of the Ocular Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. Global Markets Direct’s report features investigationa
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Polycystic Ovarian Syndrome - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Polycystic Ovarian Syndrome - Pipeline Review, H2 2016’, provides an overview of the Polycystic Ovarian Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. Global Markets Direct’
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Dyslipidemia - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Dyslipidemia - Pipeline Review, H2 2016’, provides an overview of the Dyslipidemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe co
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Batten Disease - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Batten Disease - Pipeline Review, H2 2016’, provides an overview of the Batten Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Batten Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Batten Disease and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Ocular Pain - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Ocular Pain - Pipeline Review, H2 2016’, provides an overview of the Ocular Pain pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe coveri
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Fabry Disease - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Fabry Disease - Pipeline Review, H2 2016’, provides an overview of the Fabry Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fabry Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fabry Disease and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Thalassemia - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Thalassemia - Pipeline Review, H2 2016’, provides an overview of the Thalassemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe coveri
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
African Trypanosomiasis - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘African Trypanosomiasis - Pipeline Review, H2 2016’, provides an overview of the African Trypanosomiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for African Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects. Global Markets Direct’s report feature
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Periodontitis - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Periodontitis - Pipeline Review, H2 2016’, provides an overview of the Periodontitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Periodontitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016’, provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and features dorma
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016’, provides an overview of the Metastatic Adenocarcinoma of The Pancreas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Metastatic Adenocarcinoma of The Pancreas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Adenocarcinoma of The Pancreas and features dorma
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016’, provides in depth analysis on Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted pipeline therapeutics. The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and mo
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016’, provides in depth analysis on Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted pipeline therapeutics. The report provides comprehensive information on the Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development h
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2016’, provides in depth analysis on Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted pipeline therapeutics. The report provides comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Bromodomain Containing Protein 4 (Protei
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H2 2016’, provides in depth analysis on A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted pipeline therapeutics. The report provides comprehensive information on the A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) , targeted therapeutics, complete with analysis by indicati
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016’, provides in depth analysis on Cell Division Protein FtsZ (ftsz) targeted pipeline therapeutics. The report provides comprehensive information on the Cell Division Protein FtsZ (ftsz), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cell Division Protein FtsZ (ftsz) targeted therapeutics development and features dormant and discontinued proj
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H2 2016’, provides in depth analysis on Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted pipeline therapeutics. The report provides comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological actio
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Pipeline Review, H2 2016’, provides in depth analysis on Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted pipeline therapeutics. The report provides comprehensive information on the Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeu
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016’, provides in depth analysis on Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted pipeline therapeutics. The report provides comprehensive information on the Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players invol
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016’, provides in depth analysis on Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted pipeline therapeutics. The report provides comprehensive information on the Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacol
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Pipeline Review, H2 2016’, provides in depth analysis on Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted pipeline therapeutics. The report provides comprehensive information on the Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releas
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2016’, provides in depth analysis on N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted pipeline therapeutics. The report provides comprehensive information on the N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history an
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) - Pipeline Review, H2 2016’, provides in depth analysis on Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1) targeted pipeline therapeutics. The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily C Member 1 (Voltage Gated Potassium Channel Subunit Kv3.1 or Voltage Gated Potassium Channel Subunit Kv4 or KCNC1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of ac
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Pipeline Review, H2 2016’, provides in depth analysis on Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted pipeline therapeutics. The report provides comprehensive information on the Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report als
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Actinium Pharmaceuticals, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Actinium Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The rep
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
arGEN-X BV - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘arGEN-X BV - Product Pipeline Review - 2016’, provides an overview of the arGEN-X BV’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by arGEN-X BV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
Arrowhead Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Arrowhead Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Arrowhead Pharmaceuticals, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Arrowhead Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
Cellceutix Corporation - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Cellceutix Corporation - Product Pipeline Review - 2016’, provides an overview of the Cellceutix Corporation’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Cellceutix Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
Circassia Pharmaceuticals Plc - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Circassia Pharmaceuticals Plc - Product Pipeline Review - 2016’, provides an overview of the Circassia Pharmaceuticals Plc’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Circassia Pharmaceuticals Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
iBio, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘iBio, Inc. - Product Pipeline Review - 2016’, provides an overview of the iBio, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by iBio, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
NanoViricides, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘NanoViricides, Inc. - Product Pipeline Review - 2016’, provides an overview of the NanoViricides, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by NanoViricides, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and infor
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
OncoMed Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘OncoMed Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the OncoMed Pharmaceuticals, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by OncoMed Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
Reliance Life Sciences Pvt. Ltd. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Reliance Life Sciences Pvt. Ltd. - Product Pipeline Review - 2016’, provides an overview of the Reliance Life Sciences Pvt. Ltd.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Reliance Life Sciences Pvt. Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. T
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
Sage Therapeutics, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Sage Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Sage Therapeutics, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sage Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using da
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across gl
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
Stemline Therapeutics, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Stemline Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Stemline Therapeutics, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Stemline Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is bu
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
Xencor, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Xencor, Inc. - Product Pipeline Review - 2016’, provides an overview of the Xencor, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Xencor, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from G
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016’, provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape. The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Mac
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Optic Neuropathy - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Optic Neuropathy - Pipeline Review, H2 2016’, provides an overview of the Optic Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Bronchopulmonary Dysplasia - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Bronchopulmonary Dysplasia - Pipeline Review, H2 2016’, provides an overview of the Bronchopulmonary Dysplasia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. Global Markets Direct’s re
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Raynauds Disease - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Raynauds Disease - Pipeline Review, H2 2016’, provides an overview of the Raynauds Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Hemorrhagic Shock - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Hemorrhagic Shock - Pipeline Review, H2 2016’, provides an overview of the Hemorrhagic Shock pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemorrhagic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemorrhagic Shock and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016’, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Inflamm
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Trigeminal Neuralgia - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Trigeminal Neuralgia - Pipeline Review, H2 2016’, provides an overview of the Trigeminal Neuralgia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Trigeminal Neuralgia and features dormant and discontinued projects. Global Markets Direct’s report features investigat
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Seborrhea - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Seborrhea - Pipeline Review, H2 2016’, provides an overview of the Seborrhea pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seborrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2016’, provides an overview of the Fibrinogen Deficiency (Factor I Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and featur
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Cat Allergy - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Cat Allergy - Pipeline Review, H2 2016’, provides an overview of the Cat Allergy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cat Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cat Allergy and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe coveri
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline Review, H2 2016’, provides an overview of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key pla
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Osteoarthritis - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Osteoarthritis - Pipeline Review, H2 2016’, provides an overview of the Osteoarthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016’, provides an overview of the Idiopathic (Essential) Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic (Essential) Hypertension and features dormant and discontinued proj
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Restenosis - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Restenosis - Pipeline Review, H2 2016’, provides an overview of the Restenosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Restenosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Restenosis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering o
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Encephalomyelitis - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Encephalomyelitis - Pipeline Review, H2 2016’, provides an overview of the Encephalomyelitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Encephalomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Becker Muscular Dystrophy - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Becker Muscular Dystrophy - Pipeline Review, H2 2016’, provides an overview of the Becker Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. Global Markets Direct’s report
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016’, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in ther
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Lipodystrophy - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Lipodystrophy - Pipeline Review, H2 2016’, provides an overview of the Lipodystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lipodystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lipodystrophy and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2016’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features d
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016’, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Juvenile Macular Degeneration (Starg
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Perennial Allergic Rhinitis - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Perennial Allergic Rhinitis - Pipeline Review, H2 2016’, provides an overview of the Perennial Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Perennial Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Perennial Allergic Rhinitis and features dormant and discontinued projects. Global Markets Direct’
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Rhinovirus Infections - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Rhinovirus Infections - Pipeline Review, H2 2016’, provides an overview of the Rhinovirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rhinovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhinovirus Infections and features dormant and discontinued projects. Global Markets Direct’s report features invest
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Coronaviridae Infections - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Coronaviridae Infections - Pipeline Review, H2 2016’, provides an overview of the Coronaviridae Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Coronaviridae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronaviridae Infections and features dormant and discontinued projects. Global Markets Direct’s report fea
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Premature Labor (Tocolysis) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Premature Labor (Tocolysis) - Pipeline Review, H2 2016’, provides an overview of the Premature Labor (Tocolysis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. Global Markets Direct’
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Epilepsy - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Epilepsy - Pipeline Review, H2 2016’, provides an overview of the Epilepsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 t
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Arrhythmias - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Arrhythmias - Pipeline Review, H2 2016’, provides an overview of the Arrhythmias pipeline landscape. The report provides comprehensive information on the therapeutics under development for Arrhythmias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe coveri
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $2000
Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016’, provides in depth analysis on Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted pipeline therapeutics. The report provides comprehensive information on the Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neuronal Acetylcholine Receptor Subunit Bet
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) targeted pipeline therapeutics. The report provides comprehensive information on the Integrin Alpha 7 (ITGA7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct’s rep
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Pipeline Review, H2 2016’, provides in depth analysis on Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted pipeline therapeutics. The report provides comprehensive information on the Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB o
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Pipeline Review, H2 2016’, provides in depth analysis on Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) targeted pipeline therapeutics. The report provides comprehensive information on the Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and mo
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline Review, H2 2016’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted pipeline therapeutics. The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) , targeted therapeutics
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Pipeline Review, H2 2016’, provides in depth analysis on Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacologi
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016’, provides in depth analysis on Matrix Protein 1 (M1 or M) targeted pipeline therapeutics. The report provides comprehensive information on the Matrix Protein 1 (M1 or M), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Matrix Protein 1 (M1 or M) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Amyloid Precursor Protein (APP) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Amyloid Precursor Protein (APP) - Pipeline Review, H2 2016’, provides in depth analysis on Amyloid Precursor Protein (APP) targeted pipeline therapeutics. The report provides comprehensive information on the Amyloid Precursor Protein (APP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Amyloid Precursor Protein (APP) targeted therapeutics development and features dormant and discontinued projects. G
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016’, provides in depth analysis on Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted pipeline therapeutics. The report provides comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H2 2016’, provides in depth analysis on Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted pipeline therapeutics. The report provides comprehensive information on the Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the re
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $3500
CJ HealthCare Corp. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘CJ HealthCare Corp. - Product Pipeline Review - 2016’, provides an overview of the CJ HealthCare Corp.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by CJ HealthCare Corp., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and infor
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Daewoong Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Daewoong Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
Eisai Co., Ltd. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Eisai Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Eisai Co., Ltd.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Eisai Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourc
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500
Jeil Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Jeil Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Jeil Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Jeil Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report
Published Date: Aug 2016
Published By: Global Markets Direct

Price: $1500

Back To Top